Okay now I agree that Hyroxychloroquine works. Ventilators have a mortality rate of 80% yet people keep trashing this drug, while people like that French doctor say it works.

Doctors at nursing home: “It’s actually going well. People are getting better,” Armstrong told NPR, adding that after just a handful of days, some of the 39 patients on the medication are showing signs of improvement.”

“Paid Professionals:

But scientists argue that relying on observational, uncontrolled evidence can be misleading and that the only way to truly prove a drug is working is through carefully controlled clinical trials. And, contrary to Armstrong’s assertion that hydroxychloroquine “has virtually no side effects,” it is known to have serious negative health impacts. That is why so many in the medical community worry about prescribing it without such proof.

#Repost “Some doctors are experimenting with adding nitric oxide to the mix, to help improve blood flow and oxygen to the least damaged parts of the lungs.”

Ironically enough nitric oxide improves blood oxygen flow, and also clears blood clots. Some patients who survive COVID19 have clots in the blood vessels in their lungs. We just have to wait and see.

---

(NEW YORK) — As health officials around the world push to get more ventilators to treat coronavirus patients, some doctors are moving away from using the breathing machines when they can. The reason: Some hospitals have reported unusually high death rates for coronavirus patients on ventilators, and some doctors worry that the machines could be harming certain patients.

Read more: Front Line Workers Tell Their Own Stories in the New Issue of TIME

The evolving treatments highlight the fact that doctors are still learning the best way to manage a virus that emerged only months ago. They are relying on anecdotal, real-time data amid a crush of patients and shortages of basic supplies.

A novel coronavirus (COVID-19 virus) outbreak has caused a global pandemic resulting in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral replication/transcription machinery and appears to be a primary target for the antiviral drug, remdesivir. We report the cryo-EM structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-Å resolution. In addition to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified β-hairpin domain at its N terminus. A comparative analysis model shows how remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp.

Corona Virus Disease 2019 (COVID-19) caused by a novel coronavirus emerged in December 2019 (1–3) and has since become a global pandemic. COVID-19 virus is reported to be a new member of the betacoronavirus genus and is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV) and to several bat coronaviruses (4). Compared to SARS-CoV and MERS-CoV, COVID-19 virus exhibits faster human-to-human transmission, thus leading to the WHO declaration of a world-wide public health emergency (1, 2).

CoVs employ a multi-subunit replication/transcription machinery. A set of non-structural proteins (nsp) produced as cleavage products of the ORF1a and ORF1ab viral polyproteins (5) assemble to facilitate viral replication and transcription. A key component, the RNA-dependent RNA polymerase (RdRp, also known as nsp12), catalyzes the synthesis of viral RNA and thus plays a central role in the replication and transcription cycle of COVID-19 virus, possibly with the assistance of nsp7 and nsp8 as co-factors (6). Nsp12 is therefore considered a primary target for nucleotide analog antiviral inhibitors such as remdesivir, which shows potential for the treatment of COVID-19 viral infections (7, 8). To inform drug design we have determined the structure of nsp12, in complex with its cofactors nsp7 and nsp8 by cryo-Electron Microscopy (Cryo-EM) using two different protocols, one in the absence of DTT (Dataset-1) and the other in the presence of DTT (Dataset-2).

A 29-year-old coronavirus patient has improved from serious to serious, but stable condition after receiving multiple doses of plasma from a donor who recovered from coronavirus.

---

A 29-year-old haredi (ultra-Orthodox) coronavirus patient who is being treated at Samson Assuta Ashdod University Hospital has improved from serious to serious but stable condition, after receiving multiple doses of plasma over the weekend from a donor who recovered from coronavirus, a spokesperson for the hospital told The Jerusalem Post.

On Friday, “with the assistance of Health Minister Ya’acov Litzman and his assistant, a suitable donor, a resident of Jerusalem, was found,” explained MDA director-general Eli Bin.

Some hospitals have reported unusually high death rates for coronavirus patients on ventilators, and some doctors worry that the machines could be harming certain patients. When people talk of the safety of medicines, they need to also talk of the safety of ventilators as the wrong treatment can kill a patient, and we have enough evidence that ventilators are not working.

---

NEW YORK (AP) — As health officials around the world push to get more ventilators to treat coronavirus patients, some doctors are moving away from using the breathing machines when they can.

The reason: Some hospitals have reported unusually high death rates for coronavirus patients on ventilators, and some doctors worry that the machines could be harming certain patients.

The evolving treatments highlight the fact that doctors are still learning the best way to manage a virus that emerged only months ago. They are relying on anecdotal, real-time data amid a crush of patients and shortages of basic supplies.

Rhode Island resident and professional diver Michael Lombardi said the rebreather technology he uses for deepwater dives could be used by health-care professionals battling the coronavirus.

The 15-year-old boy, a Yanomami from the village of Rehebe on the Uraricoera River, died Thursday, according to Brazil’s Ministry of Health.

He had been in the intensive care unit in Roraima General Hospital in Boa Vista, the capital of Roraima state, since April 3. The hospital has not revealed his cause of death, the Ministry of Health said.